Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …

Programmed cell death 1 (PD-1) blockade is considered contraindicated in liver transplant
(LT) recipients due to potentially lethal consequences of graft rejection and loss. Though …

Hepatocellular carcinoma remains a global health challenge affecting close to 1 million
cases yearly. Liver transplantation provides the best long‐term outcomes for those meeting …

Simple Summary Hepatocellular carcinoma (HCC) represents one of the main indications
for liver transplantation. Over recent years, immune checkpoint inhibitor (ICI) therapy has …

Rising global incidence, limited treatment options, and high lethality remain defining
characteristics of hepatocellular carcinoma (HCC).(1) Surgical and ablative treatments are …

Background A combination of tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies with
local regional therapy has elicited yield substantial clinical benefits in patients who have …

Simple Summary Hepatocellular Carcinoma (HCC) is one of the most common
malignancies in the world with increasing prevalence. This review addresses the current …

Background Atezolizumab plus Bevacizumab combination therapy has recently emerged as
the new standard of care for unresectable HCC. Significant tumor burden reduction can be …

Immune checkpoint inhibitors (ICIs) may lead to rejection and even graft loss of solid organ
transplant recipients, making them not widely used in transplant patients. There is …

Simple Summary Immune checkpoint inhibitors (ICI) have revolutionized the treatment of
hepatocellular carcinoma (HCC). In addition to their role in advanced HCC, there is …